What is Function Oncology?
Function Oncology operates at the intersection of advanced biotechnology and clinical oncology. The company utilizes a sophisticated platform for CRISPR-powered personalized functional genomics, enabling the assessment of target vulnerabilities directly within patient clinical samples. Unlike traditional diagnostic methods that rely solely on static genetic sequencing, Function Oncology provides a dynamic view of disease drivers. This methodology allows for the identification of therapeutic opportunities that remain inaccessible through conventional screening, effectively transforming how clinicians approach complex cancer cases. By focusing on individualized assessment, the company aims to improve patient outcomes while simultaneously generating high-value data to inform the development of next-generation therapies.
How much funding has Function Oncology raised?
Function Oncology has raised a total of $28M across 1 funding round:
Series A
$28M
Series A (2023): $28M with participation from Section 32 and Casdin Capital
Key Investors in Function Oncology
Section 32
Section 32 is a venture capital firm founded by Bill Maris that focuses on investing in cutting-edge technology and life sciences, supporting visionary entrepreneurs at the forefront of technological advancement.
Casdin Capital
Casdin Capital is a specialized investment firm that brings deep expertise and a long-term perspective to financing the next generation of life science innovation, particularly in diagnostics and molecular information.
What's next for Function Oncology?
With the recent influx of capital, Function Oncology is poised to transition from its current development phase into a broader clinical application stage. The strategic roadmap includes scaling its functional genomics platform to accommodate larger clinical datasets and deepening its research into critical disease drivers. As the company continues to refine its diagnostic capabilities, it is expected to forge additional partnerships with pharmaceutical entities seeking to leverage its unique insights for drug discovery. The focus remains on operational excellence and the validation of its platform across diverse oncology indications, ensuring that the company remains at the forefront of the precision medicine revolution.
See full Function Oncology company page
